Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting

被引：0
|
作者：
Ray, J. A.
Valentine, W. J.
Goodall, G.
Aagren, M.
Kotchie, R. W.
机构：
[1] IMS Hlth, Hlth Econ Dept, Basel, Switzerland
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[3] IMS Hlth, Hlth Econ Dept, London, England
来源：
DIABETOLOGIA | 2007年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1033
引用
收藏
页码：S428 / S428
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of basal/bolus therapy in type-1 diabetes using insulin detemir plus insulin aspart or human soluble insulin-based basal/bolus regimens in Germany
    Valentine, WJ
    Wittrup-Jensen, KU
    Palmer, AJ
    Roze, S
    VALUE IN HEALTH, 2005, 8 (06) : A160 - A161
  • [22] Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA1c compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes
    Jones, DR
    Kim, H
    Heller, S
    Clauson, P
    DIABETOLOGIA, 2005, 48 : A92 - A93
  • [23] Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets
    Cannon, Anthony J.
    Bargiota, Alexandra
    Billings, Liana
    Hunt, Barnaby
    Leiter, Lawrence A.
    Malkin, Samuel
    Mocarski, Michelle
    Ranthe, Mattis Flyvholm
    Schiffman, Alisa
    Doshi, Ankur
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 143 - 153
  • [24] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis
    Tunis, Sandra L.
    Minshall, Michael E.
    Conner, Christopher
    McCormick, John I.
    Kapor, Jovana
    Yale, Jean-Francois
    Groleau, Danielle
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) : 1273 - 1284
  • [25] Cost-effectiveness analyses of basal-bolus therapy of type-1 diabetes using insulin detemir plus human soluble insulin versus neutral protamine hagedorm plus human soluble insulin regimens in Germany
    Valentine, WJ
    Palmer, AJ
    Wittrup-Jensen, KU
    Roze, S
    VALUE IN HEALTH, 2005, 8 (06) : A163 - A163
  • [26] Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden
    Valentine, William J.
    Aagren, Mark
    Haglund, Mattias
    Ericsson, Asa
    Gschwend, Manuela H.
    SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2011, 39 (01) : 79 - 87
  • [27] Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (01) : 56 - 68
  • [28] Comparison of the soluble basal insulin analog insulin detemir with NPH insulin - A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy
    Hermansen, K
    Madsbad, S
    Perrild, H
    Kristensen, A
    Axelsen, M
    DIABETES CARE, 2001, 24 (02) : 296 - 301
  • [29] Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy
    Langer, Jakob
    Wolden, Michael L.
    Shimoda, Seiya
    Sato, Miki
    Araki, Eiichi
    DIABETES THERAPY, 2019, 10 (04) : 1347 - 1356
  • [30] An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK
    Palmer, Andrew J.
    Valentine, William J.
    Ray, Joshua A.
    Foos, Volker
    Lurati, Francesco
    Smith, Inger
    Lammert, Morten
    Roze, Stephane
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (04) : 895 - 901
12345